Clinical Trial

A new partnership between Nouveau Biosciences and Anova aims to fast-track a novel nanomedicine, offering a beacon of hope for patients with aggressive lymphomas.

A startling case study suggests lifelong heat exposure may build resilience against Alzheimer's. Now, medical researchers are turning to infrared saunas.

A new bispecific antibody from Kelun-Biotech and Harbour BioMed just got a green light in China, promising quarterly doses for asthma. Is this the innovation that finally unseats the market giants?

Ascletis Pharma announces a new once-daily oral obesity drug, aiming to match the power of injectables like Zepbound in a convenient pill form.

Genentech's Gazyva gains FDA Priority Review for a rare kidney disease with no approved treatments, signaling a potential paradigm shift for patients.

Kura Oncology's upcoming kidney cancer data is just the tip of the iceberg. A closer look reveals a strategic play to make darlifarnib a universal partner drug.

A U.S.-China partnership is testing a drug that could replace cataract surgery. The ZOC2017217 eye drop aims to reverse vision loss for millions.

Elevara Medicines taps biotech veteran Dr. Mai-Britt Zocca to lead its charge against rheumatoid arthritis with a novel drug and $70M in backing.

Erasca secures $550M to advance its attack on the notorious RAS/MAPK pathway. A look at the science, the strategy, and what it means for oncology.

A Norwegian biotech has dosed its first patient with a novel TCR-NK therapy, a potential breakthrough in delivering scalable, precise treatment for solid tumors.

With a new CMO, $50M in fresh capital, and pivotal trials on the horizon, Cue Biopharma makes a strategic bet on an immunology veteran to guide its future.

Voyager Therapeutics' new gene therapy just cleared a key FDA hurdle. With promising preclinical data, it's a major momentum signal in the fight against Alzheimer's.

A breakthrough study shows a wearable ear device can stimulate nerves to enhance the body’s natural clotting, offering a drug-free future for saving lives.

A Utah biotech is deploying UAE genomics and a novel drug to mimic natural immunity to Alzheimer's, signaling a strategic shift to precision prevention.

New research reveals a popular brain training app may reduce key Alzheimer's biomarkers, offering a potential non-drug path to combat neurodegeneration.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.

A Swiss biotech's oral drug just showed it can cross into the human brain and alter its activity, a key de-risking step in a high-stakes pivot.

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

This Monday, Q32 Bio will unveil pivotal data for its alopecia areata drug. For 700,000 Americans, it could mean a new path beyond today's treatments.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.